ABSTRACT

Objective: To compare the incidence of acute otitis media among children aged 2 to 6 months old in Sampaloc, Manila who were previously given 3 doses of pneumococcal conjugate vaccine (Non-Typeable \textit{Haemophilus influenzae} (NTHi) protein D, diphtheria or tetanus toxoid conjugates) and those who did not receive the vaccine over a period of one year.

Methods:

Design: Cohort Study
Setting: Primary Health Center in Sampaloc, Manila, Philippines
Participants: Medical records of well children aged 2 to 6 months were reviewed for inclusion. Participants were categorized into vaccinated and unvaccinated groups. Both groups underwent baseline history and physical examination including otoscopy and any signs and symptoms of active ear infection were noted. Subjects were followed up for a period of one year on a monthly basis for signs or symptoms of acute otitis media.

Results: A total of 176 subjects participated in the study. The overall incidence of AOM among participants was 5.11\% (9 out of 176). An AOM incidence of 3.75\% (3 out of 80) and 6.25\% (6 out of 96) was found among the exposed and unexposed groups, respectively. Fisher’s exact test (one-tailed) p value = .34, relative risk (RR) .6 (95\% CI 0.155, 2.323).

Conclusion: The results of this study showed no difference in the development of AOM in the two groups. However, based on the relative risk, Pneumococcal conjugate vaccine is still beneficial in preventing AOM in children.

Keywords: Pneumococcal Conjugate Vaccine; Acute Otitis Media

Pneumococcal Conjugate Vaccine (Non-Typeable \textit{Haemophilus influenzae} (NTHi) Protein D, Diphtheria or Tetanus Toxoid Conjugates) in Prevention of Acute Otitis Media in Children: A Cohort Study

---

Pneumococcal Conjugate Vaccine (Non-Typeable \textit{Haemophilus influenzae} (NTHi) Protein D, Diphtheria or Tetanus Toxoid Conjugates) in Prevention of Acute Otitis Media in Children: A Cohort Study

Trixy G. Chu, MD¹
Daniel Rafael R. Cachola III, MD²
Mary Agnes S. Regal, MD¹
Agnes Cecille G. Llamas, MD¹
Norberto V. Martinez, MD²
Wilfredo R. Santos, MD²

¹Department of Pediatrics
University of Santo Tomas Hospital
²Department of Otorhinolaryngology
Head and Neck Surgery
University of Santo Tomas Hospital

Correspondence: Dr. Daniel Rafael R. Cachola III
Department of Otorhinolaryngology
Head and Neck Surgery
University of Santo Tomas Hospital
España Blvd., Sampaloc, Manila 1015
Philippines
Phone: (632) 731 3001 local 2411
Email: archangel_00011@yahoo.com

The authors declared that this represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere, in full or in part, in print or electronic media; that the manuscript has been read and approved by all the authors, that the requirements for authorship have been met by each author, and that each author believes that the manuscript represents honest work.

Disclosures: The authors signed disclosures that there are no financial or other (including personal) relationships, intellectual passion, political or religious beliefs, and institutional affiliations that might lead to a conflict of interest.

This study was exhibited as a Poster Presentation during the 51st Annual Convention of the Philippine Pediatric Society, Manila, Philippines, April 6, 2014 and the 32nd Meeting of the European Society of Paediatric Infectious Diseases, Dublin, Ireland May 9, 2014.

 aureus also reported in some cases. Streptococcus pneumoniae can be
isolated from up to 50% of AOM effusions and is the most common cause
of complications.2 Since heptavalent pneumococcal conjugate vaccine
(PCV-7) was incorporated into the routine immunization schedule in
the United States by mid 2000 several studies have demonstrated a
dramatic decrease in invasive pneumococcal disease.3 In March 2009, A
pneumococcal vaccine containing 10 serotype-specific polysaccharides
conjugated to Haemophilus influenzae protein D, tetanus toxoid, and
diphtheria toxoid as the carrier proteins was developed (PHiDCV10) was
licensed in the European Union (Synflorix, GlaxoSmithKline Vaccines,
Rixensart, Belgium).

Vaccines have been used to prevent pneumococcal disease
for more than 30 years. In the United States, seven pneumococcal
serotypes cause approximately 80% of invasive disease and represent
approximately 60% of middle-ear isolates in children younger than
age 2 years.4 Antibacterial treatment has shown good activity against
pneumococcal AOM, but with the recent advent of antibiotic-resistant
pneumococcal strains there is an increasing risk for serious and fatal
infections. Preventive immunization against pneumococcal disease,
especially in individuals at risk, may be preferred to treatment of
existing infections.5

We hypothesized (H1) that a population vaccinated with
Pneumococcal Conjugate Vaccine (Non-Typeable Haemophilus
influenzae (NTHi) Protein D, Diphtheria or Tetanus Toxoid Conjugates)
would have a lower incidence of Acute Otitis Media compared to an
unvaccinated group of children. We conducted this study to compare the
incidence of Acute Otitis Media among children aged 2 months to 6
months old in Sampaloc, Manila who were previously vaccinated with 3
doses of Pneumococcal conjugate vaccine (Non-Typeable Haemophilus
influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates)
and those who were not vaccinated with the vaccine over a period of
one year.

METHODS

Study Design: Cohort Study

Setting: Local Health Center in Earnshaw, Sampaloc, Manila consisting
of 30 barangays with approximately 600-700 inhabitants per barangay,
approximately one-fourth of whom were 0-71 months old. The area
was bounded by A. Lacson, Fajardo, Valencia and Earnshaw Streets on
the outskirts of the University of Santo Tomas Hospital.

Subjects

With Institutional Review and Ethics Committee approval, 188
children meeting inclusion criteria from the selected Local Health Center
in Earnshaw, Sampaloc, Manila were considered for this study. The
target sample size computed using OpenEpi Version 3.01 (Open Source
2013/04/06) was 188 using an alpha of 0.95 and power of 80%. Inclusion
criteria for the vaccinated and unvaccinated groups were well children
born term (>37 weeks-42 weeks) who were or were not previously
vaccinated with Pneumococcal Conjugate Vaccine (Non-Typeable
Haemophilus influenzae (NTHi) Protein D, Diphtheria or Tetanus Toxoid
Conjugates) between 2 to 6 months of age, respectively.

Excluded were children who were born preterm or post-term,
children with weight z scores of <2 or >2, length z scores of <2 or >2,
weight for length of <2 or >2; children suffering from chronic illness
(including chronic heart, lung, kidney, or liver disease; brain or spinal
fluid leaks), those with weakened immune system (cancer, organ or bone
marrow transplantation, children under chemotherapy or radiation
treatment, long term steroids), suffering from sickle cell disease, with
disorders of the spleen or those who underwent splenectomy.

Procedure

The investigators obtained permission to access medical records of
the pediatric subjects aged 0-71 months from the local health officer.
All available medical records were reviewed by an independent third
party. Barangay health workers personally visited potential subjects
in their homes and requested them to come to the local health center
to be seen by the investigators. Study details were discussed with the
parents or guardians of each child prior to study enlistment and written
informed consent was obtained. Subjects who met the inclusion criteria
and participated in the study were categorized by an independent third
party to the vaccinated group and the unvaccinated group. Both groups
underwent history and physical examination including otoscopy by
the investigators at the initial visit to the local health center. Any sign
and symptom of active ear infection was noted. The investigators were
blinded to the vaccinated and unvaccinated groups. The diagnosis of
acute otitis media was based on predefined clinical criteria,1 requiring
1) a history of acute onset of signs and symptoms, and 2) signs and
symptoms of middle ear inflammation. Elements of the definition
of acute otitis media were: 1) recent (within a time frame of less than
three weeks), usually abrupt onset of signs and symptoms of middle ear
inflammation; 2) any one of the following otoscopic findings: markedly
retracted tympanic membrane, distinct erythema of the tympanic
membrane, bulging of the tympanic membrane, limited or absent
mobility of the tympanic membrane, air-fluid level or air bubbles
behind the tympanic membrane, perforation with otorrhea; and 3) any
one of the following: fever, distinct otalgia (discomfort clearly referable
to the ears) that results in interference with or precludes normal
activity or sleep).1 Participating subjects were required to be brought
to the local health center and were actively monitored through clinical
examination including otoscopy by the investigators for a period of one
year on a monthly basis. The parents or guardians were also given a
list of symptoms to record and were asked to bring their children to
the study clinic for symptoms suggestive of acute otitis media. Subjects
who were unable to come to the local health center were personally
visited at home by the investigators.

Statistical Analysis

The overall incidence of acute otitis media as well as incidence of AOM
among the vaccinated and unvaccinated groups was computed. The
1-sided Fischer’s exact test was computed using the Simple Interactive Statistical Analysis (SISA) Fischer Exact test calculator (Quantitative Skills Consultancy for Research and Statistics, The Netherlands) to compare the vaccinated and unvaccinated groups. The risk ratio was also computed using MedCalc® (MedCalc Software, Belgium).

RESULTS

A total of 188 subjects were included in the study, aged between 2 months and 6 months at the time of enrolment. Of these, 176 participants completed the study while 12 participants were lost to follow-up. Out of the 176 participants, 80 were categorized to the vaccinated group and 96 were categorized to the unvaccinated group. The vaccinated group had 45 males and 35 females while the unvaccinated group had 42 males and 54 females. The mean age was 4.5 months in the vaccinated group and 5.7 months in the unvaccinated group.

The overall incidence of acute otitis media among all participants was 5.11% (9 out of 176), with incidences of 3.75% (3 out of 80) and 6.25% (6 out of 96) among the vaccinated and unvaccinated groups, respectively. The one-sided Fisher’s exact test p value = .34. Relative risk (RR) was .6 (95% CI 0.155, 2.323).

DISCUSSION

After the introduction of PCV-7 in the US, Non-typeable H. influenzae NTHi became the most common pathogen for a period of time, but an increase in non-PCV-7 S. pneumoniae was also noted. In a study by Parra et al., among bacterial etiology for AOM, 64% of samples were culture positive for bacterial pathogens with H. influenzae and S. pneumoniae as the leading causes of bacterial AOM, detected in 34% and 29% of AOM episodes, respectively. The most commonly isolated S. pneumoniae serotypes were 19A, 19F and 23F. All H. influenzae isolates were identified as non-typeable. Based on epidemiologic data from the Health Protection Agency (HPA), 35.9% of AOM cases were assumed to have been attributable to S. pneumoniae and 32.3% to NTHi. PHID-CV is a 10-valent conjugate vaccine that includes an additional 3 serotypes (1, 5, and 7F) and uses a carrier protein derived from nontypable H influenzae (NTHi) for 8 of the 10 serotypes included. By virtue of using protein D from NTHi as a carrier protein, PHID-CV may offer additional protection against NTHi, an important cause of AOM in children. In another study, a seven variant conjugate vaccine was found to be more immunogenic than the polysaccharide pneumococcal vaccines and was 80–100% effective against vaccine-type invasive disease and 50–60% effective against vaccine-type pneumococcal otitis media. Routine immunization with pneumococcal conjugate vaccines should substantially reduce the morbidity, mortality, and costs associated with pneumococcal disease in children.

This study showed no statistically significant difference in the incidence of acute otitis media between the vaccinated and unvaccinated groups. Similar results were seen in a cohort study among Australian aboriginal children, wherein the introduction of pneumococcal vaccination was not associated with significant changes in prevalence or age of onset of different otitis media outcomes or the incidence of acute otitis media or tympanic membrane perforation. In comparison to the study by Eskola et al., the vaccine reduced the number of episodes of acute otitis media from any cause by 6%, culture-confirmed pneumococcal episodes by 34%, and the number of episodes due to the serotypes contained in the vaccine by 57%. The number of episodes attributed to serotypes that were cross-reactive with those in the vaccine was reduced by 51%, whereas the number of episodes due to all other serotypes increased by 33%. Based on the relative risk in this study, pneumococcal conjugate vaccination is still beneficial in preventing AOM in children, comparable to the previous study.

This study only focused on one subset of the population and may not be representative of the entire population. Moreover, this study did not account for risk factors in developing acute otitis media such as socioeconomic status, number of household members, overcrowding, and housing conditions. Because this study diagnosed AOM clinically and did not use other methods such as tympanostomy with culture and sensitivity; it was unable to identify organisms that may have caused the disease. The observation period was limited only to one year, and some subjects may have developed AOM after the conclusion of this study. We recommend a more diverse population with a larger sample size and a longer observation period be considered by future studies.

Although the results of this study showed no difference in the incidence of AOM among the two groups, based on the relative risk, Pneumococcal conjugate vaccine may still be beneficial in preventing AOM in children.

REFERENCES